Page 295 - Drug Class Review

Drug Effectiveness Review Project

tacrine placebo NR NR 12.5% 51% 8% 30% 0% 14% Yes, but significance not reported Post randomization exclusions: Yes (6) Overall loss to follow-up: 44% Loss to follow-up differential high: Yes placebo tacrine 20% 52% NR NR Page 178 of 205

ITT: Yes NR NR NR Poor

Final Report Update 1 Authors: Wong et al. Year: 1999 ADVERSE EVENTS: Overall adverse effects reported: Elevated ALT • Anorexia • Nausea/Vomiting • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs